



Hrvatski
zavod za
zdravstveno
osiguranje

Croatian
Health
Insurance
Fund



PPRI

Pharmaceutical Pricing and
Reimbursement Information



WHO Collaborating Centre
for Pharmaceutical Pricing
and Reimbursement Policies

CROATIA



Recent and planned developments in pharmaceutical policies 2017/2018 Special topic: patient involvement in pricing and reimbursement of medicines

CHANGES IN PRICING

Price reviews:

1. **External reference pricing (ERP)** 2017 – 1,2 % price cut on all reimbursable medicines (price list was changed on July 25, 2017)
2. **Therapeutic reference pricing (TRP)** 2017 - 4,3 % price cut on all prescription medicines (price list was changed on March 1, 2018)
3. **External reference pricing (ERP)** 2018 - ongoing

Managed Entry Agreements (**MEA**) for new expensive/orphan medicines

CHANGES IN REIMBURSEMENT

The reimbursed list of medicines changes quarterly.

Number of new medicines (new INNs) included in the list:

2017:	38 + 20 expensive/orphan medicines
01-03/2018:	18 + 7 expensive/orphan medicines

OTHERS CHANGES


MEDICINAL PRODUCTS LOW is in the process of being amended.

Planned changes are related to changes in the pricing system. Decision depends on Ministry of Health.

SPECIAL TOPIC: Patient Involvement in Pricing and Reimbursement of Medicines

Ordinance establishing the criteria for inclusion of medicines on the reimbursement lists of Croatian Health Insurance Fund

Decision making process = inclusion of medicines on the reimbursement lists (pricing & reimbursement)



Patients/citizens/insured persons and patient organisations have the opportunity to make suggestions and give **their opinion during the P&R**. Their suggestions can be useful. They are not actively involved in decision making process. Patient representative is involved in CHIF Management Board, but **not practically actively involved in final decision making process**.

Potentially involvement of patients in HTA procedures:

Patient organisations involvement was envisaged in The Croatian Guideline for Health Technology Assessment Process and Reporting (1st ed Zagreb, February 2011). In Patient organisations template patients organisation representatives are asked to describe the challenges patients face in living with disease, experiences of using health technologies that are currently available and expectations and potential benefits/drawbacks concerning the health technologies being assessed. As written in this document, „A Code of Practice for declaring and dealing with conflicts of interest in HTA process” and „Form for disclosure of potential conflict of interest in Health Technology Assessment (HTA) process” is asked to fill in.